Results 71 to 80 of about 23,046 (242)

Vaginal Laser Treatment for Genitourinary Syndrome of the Menopause: A Dose‐Determining Study in Breast Cancer Survivors

Lasers in Surgery and Medicine, EarlyView.
ABSTRACT Objectives Breast cancer survivors (BCSs) receiving endocrine therapy frequently develop genitourinary syndrome of menopause, characterized by vaginal dryness, pain, and urinary symptoms. Fractional CO2 vaginal laser therapy has been proposed as a non‐hormonal management option, but the optimal number of treatment sessions remains unclear.
Sine Jacobsen, Marianne Glavind‐Kristensen, Anders Bonde Jensen, Axel Forman, Vibe Munk Bertelsen, Pinar Bor   +5 more
wiley   +1 more source

Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy

, 2009
SA Kingsberg¹, S Kellogg², M Krychman³1University Hospitals Case Medical Center, Case Western Reserve University Cleveland OH, USA; 2The Pelvic and Sexual Health Institute of Philadelphia, Drexel University College of Medicine,
SA Kingsberg, M Krychman, S Kellogg
core  

Deep dyspareunia and central sensitization in endometriosis: A prospective study with online daily pain diary

Journal of Endometriosis and Uterine Disorders
Objective: A role for central sensitization has been suggested for endometriosis-associated deep dyspareunia. We explored the relationship between prospective deep dyspareunia scores with pain-pressure threshold (PPT) and bladder/pelvic floor tenderness (
Natasha L. Orr, Michelle Lisonek, Heather Noga, Catherine Allaire, Mohamed A. Bedaiwy, Sarka Lisonkova, Kelly B. Smith, Paul J. Yong   +7 more
doaj   +1 more source

Evolving Sacrocolpopexy Technique Trends

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Sacrocolpopexy (SCP) is widely considered the gold standard procedure for repairing apical and multi‐compartment prolapse. Despite its long‐standing and widespread use, significant technical variations persist, yet these differences have not been well‐characterized or linked to surgical outcomes.
Christina Sze, Carolina Martinez Fernandez, Gabriel Andino, Maali LaFrance Frater, Stephanie Sansone, Sonia Bhandari Randhawa, Gary E. Lemack, Ramy Goueli, Maude Carmel   +8 more
wiley   +1 more source

Biopsychosocial Profile of Women With Dyspareunia

, 1997
Objective: To compare biopsychologic profiles of women with dyspareunia with a matched no-pain control sample, and to determine whether dyspareunia subtypes based on physical findings have different psychosocial profiles from matched controls.
Cohen, Deborah, Binik, Yitzchak M., Khalife, Samir, Meana, Marta   +3 more
core   +1 more source

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast

, 2013
Lin H Soe, Gregory T Wurz, Chiao-Jung Kao, Michael W DeGregorio Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, University of California, Davis, Sacramento, CA, USA Abstract: Ospemifene is a selective estrogen ...
Wurz GT, DeGregorio MW, Kao CJ, Soe LH
core  

The Role of Vaginal Oestrogen Therapy in Postmenopausal Women With Pelvic Organ Prolapse: Does It Have Any Impact on Perioperative Outcomes? A Systematic Review of Randomised Controlled Trials

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Pelvic organ prolapse (POP) affects up to 50% of postmenopausal women, negatively impacting sexual function and quality of life. While surgery remains the primary treatment, increasing attention has been given to perioperative vaginal oestrogen therapy and its potential impact on surgical outcomes.
Gilda Sicilia, Salvatore Giovanni Vitale, Maurizio Nicola D'Alterio, Stefania Saponara, Francesco Scicchitano, Anna Maria Fulghesu, Rossella E. Nappi, Stefano Angioni   +7 more
wiley   +1 more source

Vaginal plethysmography in women with dyspareunia

, 1998
We investigated by means of vaginal plethysmography the extent to which the genital reactions of women with dyspareunia (N = 18) differed from those of women without dyspareunia (N = 16) during sexual arousal.
van de Wiel, HBM; id_orcid, van de Wiel, HBM, Schultz, WCMW, Bakker, Riksta M, Wouda, JC, Hartman, Petra M, Bakker, JO   +6 more
core   +1 more source

Women's and Health Care Professionals' Experiences of Discontinuing Hormone Replacement Therapy (HRT): A Systematic Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Hormone Replacement Therapy (HRT) is used to manage menopausal symptoms, particularly vasomotor symptoms (VMS). HRT prescribing rates are rising, but most women will eventually discontinue. Objectives To explore the experiences of women stopping HRT, why women restart HRT, and the HCPs advising them. Search Strategy Embase, MEDLINE,
Sarah Bunnewell, Sabrina Keating, Jo Parsons, Martha Hickey, Sarah Hillman   +4 more
wiley   +1 more source

Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause

, 2014
Gregory T Wurz, Chiao-Jung Kao, Michael W DeGregorio Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis, Sacramento, CA, USA Abstract: During the menopausal transition, women experience a number of ...
Wurz GT, DeGregorio MW, Kao CJ
core